Viracta Therapeutics Inc (VIRX)

Dec 17, 2024

Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com

Dec 17, 2024

Dec 15, 2024

Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World

Dec 15, 2024

Dec 13, 2024

Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register

Dec 13, 2024

Dec 11, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia

Dec 11, 2024

Dec 11, 2024

Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR

Dec 11, 2024

Dec 10, 2024

Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com

Dec 10, 2024

Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia

Dec 01, 2024

Dec 01, 2024

Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com

Dec 01, 2024

Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India

Nov 23, 2024

Nov 23, 2024

Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada

Nov 23, 2024

Nov 22, 2024

Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World

Nov 22, 2024

Nov 17, 2024

Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World

Nov 17, 2024

Nov 15, 2024

VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK

Nov 15, 2024

Nov 14, 2024

Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks

Nov 14, 2024

Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024

Nov 13, 2024

Sunesis: Q3 Earnings Snapshot - mySA

Nov 13, 2024

Nov 13, 2024

Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024

Nov 13, 2024

Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech

Nov 13, 2024

Nov 13, 2024

Viracta Cuts Workforce 42%, Narrows Focus on PTCL Drug as Cash Runway Tightens - StockTitan

Nov 13, 2024

Nov 13, 2024

Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR

Nov 13, 2024

Nov 08, 2024

Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter

Nov 08, 2024

Nov 07, 2024

VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK

Nov 07, 2024

Nov 07, 2024

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times

Nov 07, 2024

Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com

Nov 06, 2024

Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada

Nov 06, 2024

Nov 06, 2024

Viracta Therapeutics Announces Reprioritization of - GlobeNewswire

Nov 06, 2024

Nov 06, 2024

Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan

Nov 06, 2024

Nov 04, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance

Nov 04, 2024

Oct 28, 2024

T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic

Oct 28, 2024

Oct 24, 2024

Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 24, 2024

Oct 22, 2024

Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR

Oct 22, 2024

Oct 16, 2024

Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Oct 16, 2024

Oct 10, 2024

Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR

Oct 10, 2024

Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India

Sep 30, 2024

Sep 19, 2024

Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech

Sep 19, 2024

Sep 11, 2024

Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter

Sep 11, 2024

Sep 09, 2024

The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle

Sep 09, 2024

Sep 04, 2024

Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle

Sep 04, 2024

Sep 03, 2024

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 03, 2024

Sep 02, 2024

Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News

Sep 02, 2024

Sep 02, 2024

Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 02, 2024

Sep 02, 2024

What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News

Sep 02, 2024

Aug 29, 2024

Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News

Aug 29, 2024

Aug 28, 2024

Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News

Aug 28, 2024

Aug 27, 2024

Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Aug 27, 2024

Aug 23, 2024

Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com

Aug 23, 2024